Top Section/Ad
Top Section/Ad
Most recent
Sfr4.9bn trade is largest European ECM deal since National Grid’s £7bn rights issue in 2024
Offer came as markets recovered and volatility fell
Abbott Laboratories plundered $20bn as it led a trio of drug companies which printed jumbo bonds as a deluge of supply in the dollar market ensured a red-hot end to the month.
More articles/Ad
More articles/Ad
More articles
-
Credit spreads for corporate borrowers from sectors that will benefit the most from reopening from lockdowns are drifting wider as coronavirus infections rise thanks to the spread of the delta variant. Industries already battered by the pandemic face a rough autumn in capital markets if there is another major global wave of the virus. -
HK Inno.N Corp, a South Korean pharmaceuticals company known for its popular hangover tonics, has priced its IPO at the top of the marketed range, netting W596.9bn ($520.9m).
-
Idorsia, the Swiss biotech company, has turned to the convertible bond market to finance looming product launches and the development of its late-stage drug pipeline.
-
Chinese biopharmaceutical company I-Mab is moving ahead with plans for a dual listing in Shanghai, as it looks to broaden its investor base.
-
Hong Kong’s stock exchange has rejected an IPO application from Aim Vaccine, a leading Chinese vaccine maker. The deal is being sponsored by China Securities, CICC, Goldman Sachs and Macquarie.
-
Pharmaceutical ingredients manufacturer Glenmark Life Sciences is set to launch a Rp15.1bn ($202.6m) IPO on Tuesday.
